This is Part 2 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with relapsed multiple myeloma. The patient is an 80-year-old woman with hematocrit of 30, compression fractures in the thoracic and lumbar spine, and normal calcium and renal function. A bone marrow biopsy shows 80% plasma cells with hyperdiploidy; her IgA is 1,600 mg/dL, and the kappa:lambda ratio is 200. She receives RVD-lite, achieving a very good partial response. However, 2 years later, her IgA and kappa:lambda ratio are found to be increasing.

 

In the conversation that follows, the faculty discuss the optimal salvage therapy for this patient, the role that chimeric antigen receptor T-cell therapies play at first relapse, and the impact of frailty status on choice of therapy.